Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its Phase 2 clinical trial for CPI-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. The multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. The trial is currently open through The University of Michigan Health Rogel Cancer Center as an investigator-sponsored trial. The trial is also open at Fred Hutchinson Cancer Research Center and UT Southwestern Simmons Cancer Center. Rafael is also launching additional sites for the trial at Northwestern University Lurie Cancer Center, UH Seidman Cancer Center, The University of Arizona Cancer Center, University of Wisconsin Carbone Cancer Center, Vanderbilt-Ingram Cancer Center, Atlantic Health System Cancer Care, and Allegheny Health Network Cancer Institute.
“We are pleased that our Phase 2 trial has continued to see a positive enrollment rate, demonstrating devimistat’s ability to serve as a catalyst for hope and potential relief to families affected by this harrowing condition,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “We are happy to report a continuation of safety within the trial, as the wellbeing of our patients is our top priority.”
“Biliary tract cancer is considered a very rare and aggressive form of cancer, with fewer than 20,000 U.S. cases per year and a 5-year survival rate of less than 5%,” said Dr. Vaibhav Sahai, MBBS, M.S., principal investigator on the trial and medical oncologist at the University of Michigan Rogel Cancer Center. “The research community remains engaged towards identifying devimistat’s capabilities in biliary cancer which is being reflected through the strong and continued Phase 2 enrollment rate, and we’re hopeful that the opening of our additional sites will allow families and their loved ones affected by biliary tract cancer an effective treatment option.”
About CPI-613® (Devimistat)
About Rafael Pharmaceuticals, Inc.
Safe Harbor Statement
In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Media Contact: Morrena Villanueva [email protected] (609) 201-3408
Harmonizing the Data from the Factory Floor
Driving Production Lessons from the Automotive Industry
Total Addressable Market for Your Solution